for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascletis Pharma Inc

1672.HK

Latest Trade

3.95HKD

Change

-0.12(-2.95%)

Volume

9,978,000

Today's Range

3.89

 - 

4.11

52 Week Range

2.80

 - 

8.69

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.07
Open
4.05
Volume
9,978,000
3M AVG Volume
254.04
Today's High
4.11
Today's Low
3.89
52 Week High
8.69
52 Week Low
2.80
Shares Out (MIL)
1,106.34
Market Cap (MIL)
4,591.29
Forward P/E
--
Dividend (Yield %)
--

Next Event

Ascletis Pharma Inc Annual Shareholders Meeting

Latest Developments

More

Ascletis Pharma Says Application For Category I Drug ASC41 Developed Accepted By NMPA Of PRC

Ascletis Pharma Syas Ritonavir Gets Approval From For Study On Treatment Of Novel Coronavirus Pneumonia

Ascletis Pharma Says Trial Evaluating Efficiency Of Asc09/Ritonavir Fixed-Dose Combination, Ritonavir Approved

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascletis Pharma Inc

Ascletis Pharma Inc. is a China-based company principally engaged in the research and development of biological products. The Company is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Executive Leadership

Jinzi Jason Wu

Executive Chairman of the Board, Chief Executive Officer

Handan He

Chief Scientific Officer

Judy Hejingdao Wu

Vice President, Executive Director

Yuemei Yan

Vice President of Sales

Yi Chen

Vice President

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

0.2K

2019(E)

0.5K
EPS (HKD)

2018

-0.010

2019(E)

-0.001
Price To Earnings (TTM)
--
Price To Sales (TTM)
32.59
Price To Book (MRQ)
1.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.16
LT Debt To Equity (MRQ)
0.10
Return on Investment (TTM)
-4.18
Return on Equity (TTM)
-4.02

Latest News

Latest News

BRIEF-Ascletis Pharma Syas Ritonavir Gets Approval From For Study On Treatment Of Novel Coronavirus Pneumonia

* RITONAVIR GETS APPROVAL FROM REGULATORY AUTHORITIES OF ZHEJIANG PROVINCE FOR STUDY ON TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA Source text for Eikon: Further company coverage:

BRIEF-Ascletis Pharma Says ASC09 Fixed-Dose Combination Obtained Approval To Conduct Clinical Trial

* ASC09 FIXED-DOSE COMBINATION OBTAINED APPROVAL TO CONDUCT CLINICAL TRIAL ON TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up